Here authors identify RSK1 as a vulnerability for MPN and sAML and show the efficacy of a first-in-class RSK inhibitor, PMD-026, against these types of myeloid malignancies.
Charleston AMC joined the ACCC MPN Quality Improvement Program to improve symptom tracking for MPN patients using the MPN-SAF TSS tool. The MPN-SAF TSS tool helps patients rate symptom severity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback